2024

July Technology transfer of NXC736 to Pluto (New indication)

June IND approval for Phase 1 clinical trial of NXC680

April Government funding for NXC736 Phase II clinical trial by KDDF

2023

October IND approval for Phase 2 clinical trial of NXC736

January NXC680 designated as an orphan drug by the U.S. FDA

2022

December Completion of Phase 1 clinical trial for NXC736

December Series B-ext funding

2021

December Strategic investment

August IND approval for Phase 1 clinical trial of NXC736 in Korea

2020

July Series B funding
Government funding for RIPF treatment R&D by Ministry of Science and ICT

April Government funding for advanced medical technology R&D by Ministry of Health and Welfare

2019

July Series A funding

2018

December Pre-A funding

August Founded